nach oben

Journal of Endocrinological Investigation

Erschienen in:

06.11.2023 | Original Article

Alterations of cardiometabolic risk profile in polycystic ovary syndrome: 13 years follow-up in an unselected population

verfasst von: S. Aksun, N. C. Sonu, S. Aygun, U. N. Karakulak, S. Mumusoglu, B. O. Yildiz

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cardiometabolic risk factors are common in women with polycystic ovary syndrome (PCOS) during reproductive years. The aim of this study was to determine the impact of aging on cardiometabolic risk of the syndrome by examining women who had previously been diagnosed to have PCOS or to be healthy in an unselected population in 2009.

Participants

Forty-one women with PCOS who were diagnosed and phenotyped according to the Rotterdam criteria and 43 age- and body mass index (BMI)-matched healthy women from the same unselected cohort.

Methods

All participants were evaluated by structured interview, physical examination, anthropometric, hormonal and biochemical measurements. Additionally, body composition analyses and echocardiographic assessments of 30 women with PCOS and 30 control women were conducted at 13 years of follow-up.

Results

There was no difference between the patient and the control groups in terms of anthropometric and body composition measures and metabolic parameters. Echocardiographic assessment showed similar systolic functions, strain measurements and epicardial fat measurements between the groups. PCOS patients still had higher levels of total testosterone, free androgen index (FAI) and dehydroepiandrosterone sulfate (DHEAS) levels compared to controls. Epicardial fat thickness showed positive correlations with BMI, total and truncal body fat, homeostatic model assessment for insulin resistance (HOMA-IR) and free androgen index (FAI).

Conclusions

Aging women with PCOS in the population have higher androgen levels and similar cardiometabolic risk profile compared to age- and BMI-matched healthy women. Epicardial fat thickness, a marker of cardiometabolic risk, appear to be associated with hyperandrogenism. Further research is needed on larger community-based cohorts where older patients are assessed with a longer follow-up.

Pasquali R, Stener-Victorin E, Yildiz BO, Duleba AJ, Hoeger K, Mason H, Homburg R, Hickey T, Franks S, Tapanainen JS, Balen A, Abbott DH, Diamanti-Kandarakis E, Legro RS (2011) PCOS Forum: research in polycystic ovary syndrome today and tomorrow. Clin Endocrinol (Oxf) 74(4):424–433. https://doi.org/10.1111/j.1365-2265.2010.03956.xCrossRefPubMed

Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H (2012) Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 27(10):3067–3073. https://doi.org/10.1093/humrep/des232CrossRefPubMed

Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowtiz B, Teede HJ, Yildiz BO (2016) Polycystic ovary syndrome. Nat Rev Dis Primers. https://doi.org/10.1038/nrdp.2016.57CrossRefPubMed

Helvaci N, Yildiz BO (2022) The impact of ageing and menopause in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 97(3):371–382. https://doi.org/10.1111/cen.14558CrossRefPubMed

Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R (2016) Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril 106(1):6–15. https://doi.org/10.1016/j.fertnstert.2016.05.003CrossRefPubMed

Behboudi-Gandevani S, Ramezani Tehrani F, Hosseinpanah F, Khalili D, Cheraghi L, Kazemijaliseh H, Azizi F (2018) Cardiometabolic risks in polycystic ovary syndrome: long-term population-based follow-up study. Fertil Steril 110(7):1377–1386. https://doi.org/10.1016/j.fertnstert.2018.08.046CrossRefPubMed

Iftikhar S, Collazo-Clavell ML, Roger VL, St Sauver J, Brown RD Jr, Cha S, Rhodes DJ (2012) Risk of cardiovascular events in patients with polycystic ovary syndrome. Neth J Med 70(2):74–80PubMedPubMedCentral

Kazemi Jaliseh H, Ramezani Tehrani F, Behboudi-Gandevani S, Hosseinpanah F, Khalili D, Cheraghi L, Azizi F (2017) Polycystic ovary syndrome is a risk factor for diabetes and prediabetes in middle-aged but not elderly women: a long-term population-based follow-up study. Fertil Steril 108(6):1078–1084. https://doi.org/10.1016/j.fertnstert.2017.09.004CrossRefPubMed

Polotsky AJ, Allshouse AA, Crawford SL, Harlow SD, Khalil N, Kazlauskaite R, Santoro N, Legro RS (2014) Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition. J Clin Endocrinol Metab 99(6):2120–2127. https://doi.org/10.1210/jc.2013-4170CrossRefPubMedPubMedCentral

10.

Schmidt J, Brännström M, Landin-Wilhelmsen K, Dahlgren E (2011) Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls. J Clin Endocrinol Metab 96(7):2178–2185. https://doi.org/10.1210/jc.2010-2959CrossRefPubMed

11.

Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E (2011) Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab 96(12):3794–3803. https://doi.org/10.1210/jc.2011-1677CrossRefPubMed

12.

Wild S, Pierpoint T, McKeigue P, Jacobs H (2000) Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 52(5):595–600. https://doi.org/10.1046/j.1365-2265.2000.01000.xCrossRefPubMed

13.

Macut D, Antić IB, Bjekić-Macut J (2015) Cardiovascular risk factors and events in women with androgen excess. J Endocrinol Invest 38(3):295–301. https://doi.org/10.1007/s40618-014-0215-1CrossRefPubMed

14.

Lizneva D, Kirubakaran R, Mykhalchenko K, Suturina L, Chernukha G, Diamond MP, Azziz R (2016) Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. Fertil Steril 106(6):1510–20.e2. https://doi.org/10.1016/j.fertnstert.2016.07.1121CrossRefPubMed

15.

Mumusoglu SYBO (2020) Polycystic ovary syndrome phenotypes and prevalence: Differential impact of diagnostic criteria and clinical versus unselected population. Curr Opin Endocr Metab Res 12:66–71CrossRef

16.

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes A (2023) 2. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care 46(Suppl 1):S19-s40. https://doi.org/10.2337/dc23-S002CrossRefPubMed

17.

Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42(6):1206–1252. https://doi.org/10.1161/01.HYP.0000107251.49515.c2CrossRefPubMed

18.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17):2735–2752. https://doi.org/10.1161/circulationaha.105.169404CrossRefPubMed

19.

Ozgen Saydam B, Has AC, Bozdag G, Oguz KK, Yildiz BO (2017) Structural imaging of the brain reveals decreased total brain and total gray matter volumes in obese but not in lean women with polycystic ovary syndrome compared to body mass index-matched counterparts. Gynecol Endocrinol 33(7):519–523. https://doi.org/10.1080/09513590.2017.1295440CrossRefPubMed

20.

Büttler RM, Kruit A, Blankenstein MA, Heijboer AC (2013) Measurement of dehydroepiandrosterone sulphate (DHEAS): a comparison of Isotope-Dilution Liquid Chromatography Tandem Mass Spectrometry (ID-LC-MS/MS) and seven currently available immunoassays. Clin Chim Acta. https://doi.org/10.1016/j.cca.2013.04.028CrossRefPubMed

21.

Pinola P, Piltonen TT, Puurunen J, Vanky E, Sundström-Poromaa I, Stener-Victorin E, Ruokonen A, Puukka K, Tapanainen JS, Morin-Papunen LC (2015) Androgen profile through life in women with polycystic ovary syndrome: a nordic multicenter collaboration study. J Clin Endocrinol Metab 100(9):3400–3407. https://doi.org/10.1210/jc.2015-2123CrossRefPubMed

22.

Forslund M, Schmidt J, Brännström M, Landin-Wilhelmsen K, Dahlgren E (2021) Reproductive hormones and anthropometry: a follow-up of PCOS and controls from perimenopause to older than 80 years. J Clin Endocrinol Metab 106(2):421–430. https://doi.org/10.1210/clinem/dgaa840CrossRefPubMed

23.

Merz CN, Shaw LJ, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-DeHoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ (2016) Cardiovascular disease and 10-year mortality in postmenopausal women with clinical features of polycystic ovary syndrome. J Womens Health (Larchmt) 25(9):875–881. https://doi.org/10.1089/jwh.2015.5441CrossRefPubMed

24.

Meun C, Gunning MN, Louwers YV, Peters H, Roos-Hesselink J, Roeters van Lennep J, Rueda Ochoa OL, Appelman Y, Lambalk N, Boersma E, Kavousi M, Fauser BC, Laven JS (2020) The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 92(2):150–158. https://doi.org/10.1111/cen.14117CrossRefPubMed

25.

Kakoly NS, Moran LJ, Teede HJ, Joham AE (2019) Cardiometabolic risks in PCOS: a review of the current state of knowledge. Expert Rev Endocrinol Metab 14(1):23–33. https://doi.org/10.1080/17446651.2019.1556094CrossRefPubMed

26.

Alexopoulos N, McLean DS, Janik M, Arepalli CD, Stillman AE, Raggi P (2010) Epicardial adipose tissue and coronary artery plaque characteristics. Atherosclerosis 210(1):150–154. https://doi.org/10.1016/j.atherosclerosis.2009.11.020CrossRefPubMed

27.

Mazurek T, Kiliszek M, Kobylecka M, Skubisz-Głuchowska J, Kochman J, Filipiak K, Królicki L, Opolski G (2014) Relation of proinflammatory activity of epicardial adipose tissue to the occurrence of atrial fibrillation. Am J Cardiol 113(9):1505–1508. https://doi.org/10.1016/j.amjcard.2014.02.005CrossRefPubMed

28.

Psaltis PJ, Talman AH, Munnur K, Cameron JD, Ko BSH, Meredith IT, Seneviratne SK, Wong DTL (2016) Relationship between epicardial fat and quantitative coronary artery plaque progression: insights from computer tomography coronary angiography. Int J Cardiovasc Imaging 32(2):317–328. https://doi.org/10.1007/s10554-015-0762-3CrossRefPubMed

29.

Pandurevic S, Bergamaschi L, Pizzi C, Patton L, Rucci P, Corzani F, Cecchetti C, Pelusi C, Altieri P, Vicennati V, Di Dalmazi G, Fanelli F, Macut D, Pagotto U, Gambineri A (2021) Body mass index rather than the phenotype impacts precocious ultrasound cardiovascular risk markers in polycystic ovary syndrome. Eur J Endocrinol 184(1):199–208. https://doi.org/10.1530/eje-20-0725CrossRefPubMed

30.

Millán-de-Meer M, Luque-Ramírez M, Nattero-Chávez L, Escobar-Morreale HF (2023) PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis. Hum Reprod Update. https://doi.org/10.1093/humupd/dmad015CrossRefPubMed

31.

Harmanci A, Cinar N, Bayraktar M, Yildiz BO (2013) Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome. Clin Endocrinol (Oxf) 78(1):120–125. https://doi.org/10.1111/j.1365-2265.2012.04466.xCrossRefPubMed

32.

Merz CN, Johnson BD, Berga S, Braunstein G, Reis SE, Bittner V (2006) Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation. Fertil Steril 85(5):1425–1431. https://doi.org/10.1016/j.fertnstert.2006.01.009CrossRefPubMed

33.

Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ (2010) Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study. BMJ. https://doi.org/10.1136/bmj.c927CrossRefPubMedPubMedCentral

34.

Kim C, Siscovick DS, Sidney S, Lewis CE, Kiefe CI, Koepsell TD (2002) Oral contraceptive use and association with glucose, insulin, and diabetes in young adult women: the CARDIA Study. Coronary Artery Risk Development in Young Adults. Diabetes Care 25(6):1027–1032. https://doi.org/10.2337/diacare.25.6.1027CrossRefPubMed

Titel: Alterations of cardiometabolic risk profile in polycystic ovary syndrome: 13 years follow-up in an unselected population
verfasst von: S. Aksun
N. C. Sonu
S. Aygun
U. N. Karakulak
S. Mumusoglu
B. O. Yildiz
Publikationsdatum: 06.11.2023
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 5/2024
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-023-02230-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Alterations of cardiometabolic risk profile in polycystic ovary syndrome: 13 years follow-up in an unselected population

Abstract

Purpose

Participants

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Participants

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2024

Establishment of gestational diabetes risk prediction model and clinical verification

Management of patients with extensive locally advanced thyroid cancer: results of multimodal treatments

Aromatase inhibitors: a useful additional therapeutic option for slowing down advanced bone age in boys with growth hormone deficiency

Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes

Claudin 18.2 expression in digestive neuroendocrine neoplasms: a clinicopathological study

Risks of suboptimal and excessive thyroid hormone replacement across ages

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin